BACKGROUND: Rituximab is a chimeric anti-CD20 monoclonal antibody that induces sustained remission in children with steroid-dependent nephrotic syndrome. However, there is no consensus on the optimal regimen and monitoring of rituximab. In other autoimmune diseases, anti-rituximab antibodies (ARA) have been reported in 10-40% of patients, but their clinical relevance remains unclear. In nephrotic syndrome, data are scarce. METHODS: We report a single-center retrospective study with immuno- and pharmacological monitoring of rituximab treatment in children with frequent relapsing (FR) or steroid-dependent nephrotic syndrome (SDNS). We analyzed the monthly monitoring of 24 children, receiving a dose of rituximab (375 mg/m2) between December 2017 and April 2018 at the Pediatric Nephrology Department of Robert-Debré hospital, Paris. RESULTS: ARA were detected in 7/24 patients (29%), sometimes after the first infusion of rituximab. ARA were present at baseline in two patients previously treated with rituximab. Both displayed no B-cell depletion. ARA were also reported in 5/22 patients during follow-up, with antibodies always detected in the first month following B-cell recovery. An incomplete CD19+CD20- B-cell depletion at M1 (5-25/mm3) and low serum rituximab levels was predictive of developing ARA. The development of de novo ARA during follow-up was not associated with shorter B-cell depletion. CONCLUSIONS: This study shows that ARA are frequent in children with FR/SDNS and that close immuno- and pharmacological monitoring may help personalizing rituximab treatment in patients needing repeated injections.
BACKGROUND: Rituximab is a chimeric anti-CD20 monoclonal antibody that induces sustained remission in children with steroid-dependent nephrotic syndrome. However, there is no consensus on the optimal regimen and monitoring of rituximab. In other autoimmune diseases, anti-rituximab antibodies (ARA) have been reported in 10-40% of patients, but their clinical relevance remains unclear. In nephrotic syndrome, data are scarce. METHODS: We report a single-center retrospective study with immuno- and pharmacological monitoring of rituximab treatment in children with frequent relapsing (FR) or steroid-dependent nephrotic syndrome (SDNS). We analyzed the monthly monitoring of 24 children, receiving a dose of rituximab (375 mg/m2) between December 2017 and April 2018 at the Pediatric Nephrology Department of Robert-Debré hospital, Paris. RESULTS: ARA were detected in 7/24 patients (29%), sometimes after the first infusion of rituximab. ARA were present at baseline in two patients previously treated with rituximab. Both displayed no B-cell depletion. ARA were also reported in 5/22 patients during follow-up, with antibodies always detected in the first month following B-cell recovery. An incomplete CD19+CD20- B-cell depletion at M1 (5-25/mm3) and low serum rituximab levels was predictive of developing ARA. The development of de novo ARA during follow-up was not associated with shorter B-cell depletion. CONCLUSIONS: This study shows that ARA are frequent in children with FR/SDNS and that close immuno- and pharmacological monitoring may help personalizing rituximab treatment in patients needing repeated injections.
Authors: Pietro Ravani; Roberta Rossi; Alice Bonanni; Robert R Quinn; Felice Sica; Monica Bodria; Andrea Pasini; Giovanni Montini; Alberto Edefonti; Mirco Belingheri; Donatella De Giovanni; Giancarlo Barbano; Ludovica Degl'Innocenti; Francesco Scolari; Luisa Murer; Jochen Reiser; Alessia Fornoni; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2015-01-15 Impact factor: 10.121
Authors: D Albert; J Dunham; S Khan; J Stansberry; S Kolasinski; D Tsai; S Pullman-Mooar; F Barnack; C Striebich; R J Looney; E T Luning Prak; R Kimberly; Y Zhang; R Eisenberg Journal: Ann Rheum Dis Date: 2008-02-04 Impact factor: 19.103
Authors: Chris Wincup; Madhvi Menon; Edward Smith; Ann Schwartz; David Isenberg; Elizabeth C Jury; Claudia Mauri Journal: Ann Rheum Dis Date: 2019-03-28 Impact factor: 19.103
Authors: Jon Thorkell Einarsson; Max Evert; Pierre Geborek; Tore Saxne; Maria Lundgren; Meliha C Kapetanovic Journal: Clin Rheumatol Date: 2017-10-04 Impact factor: 2.980